Home › Companies › STANDARD BIOTOOLS INC. › 2023-2024
Compiled from SEC Form N-PX filings and STANDARD BIOTOOLS INC.’s Form 8-K, filed July 1, 2024 (Item 5.07 on EDGAR). Page generated October 14, 2026.
Meeting of June 27, 2024: 5 items on STANDARD BIOTOOLS INC.’s Form 8-K, filed July 1, 2024: 2 elected · 3 approved.
Meeting of January 4, 2024: 5 items on STANDARD BIOTOOLS INC.’s Form 8-K, filed January 5, 2024: 5 without a stated outcome.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore STANDARD BIOTOOLS INC. in the interactive database Compare manager voting policies
These tallies are STANDARD BIOTOOLS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed July 1, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX. STANDARD BIOTOOLS INC. reported 2 meetings in this season; each is tabulated separately below, with its own filing.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Troy Cox | 222,829,923 | -- | -- | 7,618,480 | 62,511,542 | 97% | Elected | — |
| Elect Director: Fenel M. Eloi | 221,580,993 | -- | -- | 8,868,410 | 62,510,542 | 96% | Elected | — |
| 2. Advisory Vote on Approval of Executive Compensation | 200,835,452 | 28,960,018 | 653,932 | -- | 62,510,543 | 87% | Approved | — |
| 3. Ratification of Appointment of Independent Registered Public Accounting Firm | 291,606,384 | 383,526 | 970,035 | -- | -- | 99.8% | Approved | — |
| 4. Approval of the Amendment to the Amended and Restated 2011 Equity Incentive Plan | 219,832,074 | 10,192,031 | 425,296 | -- | 62,510,544 | 96% | Approved | — |
Source: STANDARD BIOTOOLS INC., Form 8-K, filed with the SEC on July 1, 2024 — read the filing on EDGAR.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| 1. To approve the issuance of shares of Standard BioTools Common Stock in connection with the Merger and in accordance with Nasdaq Listing Rule 5635(a) (the "Standard BioTools Share Issuance Proposal") | 125,739,416 | 5,186,617 | 127,586 | -- | -- | 96% | Not verified | — |
| 2. To approve the Charter Amendment (the "Standard BioTools Charter Amendment Proposal") | 125,698,245 | 5,230,711 | 124,663 | -- | -- | 96% | Not verified | — |
| 3. To approve, on a non-binding, advisory basis, the compensation that may become payable to Standard BioTools' named executive officers and to SomaLogic's Chief Executive Officer that is based on or otherwise relates to the Merger | 119,441,699 | 11,267,991 | 343,929 | -- | -- | 91% | Not verified | — |
| 4. To approve the A&R 2011 Plan Amendment | 119,362,194 | 11,536,749 | 154,676 | -- | -- | 91% | Not verified | — |
| 5. To approve adjournments of the Special Meeting from time to time, if necessary or appropriate, to solicit additional proxies in favor of the Standard BioTools Share Issuance Proposal and the Standard BioTools Charter Amendment Proposal if there are insuffic | 124,087,718 | 6,753,379 | 212,522 | -- | -- | 95% | Not verified | — |
Source: STANDARD BIOTOOLS INC., Form 8-K, filed with the SEC on January 5, 2024 — read the filing on EDGAR.
Each item below shows how the 141 asset managers that disclosed a STANDARD BIOTOOLS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of STANDARD BIOTOOLS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Meeting held June 27, 2024.
Combines 4 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Description as filed by funds: To vote to elect two (2) nominees as Class II Directors, each to a term expiring at our 2027 annual meeting of stockholders and to hold office until his successor is duly elected and qualified: Troy Cox
STANDARD BIOTOOLS INC.’s own tally for this item (“Elect Director: Troy Cox”): 222,829,923 for, 7,618,480 withheld, per its Form 8-K filed July 1, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The following nominees were elected to serve as Class II directors, to hold office until the Company's 2027 annual meeting of stockholders or until their respective successors have been duly elected and qualified or their earlier resignation or removal:”
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 25 asset managers below reported 39,618,945 for, 72,060 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| ARK ETF Trust | 13,046,212 | 0 | 0 | 0 | For |
| Vanguard | 12,987,923 | 0 | 0 | 0 | For |
| Morgan Stanley | 3,735,804 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 2,153,269 | 0 | 0 | 0 | For |
| Equitable | 1,786,199 | 0 | 0 | 0 | For |
| Fidelity | 1,280,779 | 0 | 0 | 0 | For |
| Neuberger Berman | 1,176,340 | 0 | 0 | 0 | For |
| NEEDHAM FUNDS INC | 950,000 | 0 | 0 | 0 | For |
| BlackRock | 866,875 | 0 | 0 | 0 | For |
| NORTHERN LIGHTS FUND TRUST II | 541,597 | 0 | 0 | 0 | For |
| PARADIGM FUNDS | 301,600 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 260,783 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 177,000 | 0 | 0 | 0 | For |
| Northern Trust | 119,504 | 0 | 0 | 0 | For |
| Charles Schwab | 111,584 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 72,060 | Withhold |
| Victory Capital | 36,686 | 0 | 0 | 0 | For |
| American Century | 26,410 | 0 | 0 | 0 | For |
| BNY Mellon | 23,182 | 0 | 0 | 0 | For |
| Invesco | 18,127 | 0 | 0 | 0 | For |
| State Street | 10,677 | 0 | 0 | 0 | For |
| John Hancock | 6,488 | 0 | 0 | 0 | For |
| Nationwide | 1,451 | 0 | 0 | 0 | For |
| Guggenheim | 454 | 0 | 0 | 0 | For |
| New York Life | 1 | 0 | 0 | 0 | For |
Meeting held June 27, 2024.
Combines 4 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: To vote to elect two (2) nominees as Class II Directors, each to a term expiring at our 2027 annual meeting of stockholders and to hold office until his successor is duly elected and qualified: Fenel M. Eloi
STANDARD BIOTOOLS INC.’s own tally for this item (“Elect Director: Fenel M. Eloi”): 221,580,993 for, 8,868,410 withheld, per its Form 8-K filed July 1, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The following nominees were elected to serve as Class II directors, to hold office until the Company's 2027 annual meeting of stockholders or until their respective successors have been duly elected and qualified or their earlier resignation or removal:”
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 25 asset managers below reported 39,322,441 for, 368,564 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| ARK ETF Trust | 13,046,212 | 0 | 0 | 0 | For |
| Vanguard | 12,987,923 | 0 | 0 | 0 | For |
| Morgan Stanley | 3,735,804 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 2,153,269 | 0 | 0 | 0 | For |
| Equitable | 1,786,199 | 0 | 0 | 0 | For |
| Fidelity | 1,280,779 | 0 | 0 | 0 | For |
| Neuberger Berman | 1,176,340 | 0 | 0 | 0 | For |
| NEEDHAM FUNDS INC | 950,000 | 0 | 0 | 0 | For |
| BlackRock | 866,875 | 0 | 0 | 0 | For |
| NORTHERN LIGHTS FUND TRUST II | 541,597 | 0 | 0 | 0 | For |
| PARADIGM FUNDS | 301,600 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 260,783 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 177,000 | Withhold |
| Northern Trust | 0 | 0 | 0 | 119,504 | Withhold |
| Charles Schwab | 111,584 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 72,060 | Withhold |
| Victory Capital | 36,686 | 0 | 0 | 0 | For |
| American Century | 26,410 | 0 | 0 | 0 | For |
| BNY Mellon | 23,182 | 0 | 0 | 0 | For |
| Invesco | 18,127 | 0 | 0 | 0 | For |
| State Street | 10,677 | 0 | 0 | 0 | For |
| John Hancock | 6,488 | 0 | 0 | 0 | For |
| Nationwide | 1,451 | 0 | 0 | 0 | For |
| Guggenheim | 454 | 0 | 0 | 0 | For |
| New York Life | 1 | 0 | 0 | 0 | For |
Meeting held January 4, 2024.
Combines 3 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: Standard BioTools Share Issuance Proposal. To approve the issuance of shares of common stock, par value $0.001 per share, of Standard BioTools ("Standard BioTools Common Stock") in connection with the Merger and in accordance with Nasdaq Listing Rule 5635(a) (the "Standard BioTools Share Issuance Proposal");
STANDARD BIOTOOLS INC.’s own tally for this item (“1. To approve the issuance of shares of Standard BioTools Common Stock in connection with the Merger and in accordance with Nasdaq Listing Rule 5635(a) (the "Standard BioTools Share Issuance Proposal")”): 125,739,416 for, 5,186,617 against, per its Form 8-K filed January 5, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 19 asset managers below reported 11,930,519 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,068,266 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 2,195,369 | 0 | 0 | 0 | For |
| Neuberger Berman | 1,468,160 | 0 | 0 | 0 | For |
| Morgan Stanley | 1,295,362 | 0 | 0 | 0 | For |
| NEEDHAM FUNDS INC | 1,190,000 | 0 | 0 | 0 | For |
| Equitable | 597,551 | 0 | 0 | 0 | For |
| Fidelity | 538,365 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 212,000 | 0 | 0 | 0 | For |
| NEXPOINT FUNDS I | 154,262 | 0 | 0 | 0 | For |
| BlackRock | 76,562 | 0 | 0 | 0 | For |
| BNY Mellon | 52,908 | 0 | 0 | 0 | For |
| Charles Schwab | 31,192 | 0 | 0 | 0 | For |
| Dimensional | 20,355 | 0 | 0 | 0 | For |
| Northern Trust | 16,964 | 0 | 0 | 0 | For |
| Victory Capital | 8,484 | 0 | 0 | 0 | For |
| Nationwide | 2,446 | 0 | 0 | 0 | For |
| John Hancock | 1,624 | 0 | 0 | 0 | For |
| Guggenheim | 454 | 0 | 0 | 0 | For |
| Series Portfolios Trust | 195 | 0 | 0 | 0 | For |
Meeting held January 4, 2024.
Combines 3 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: Standard BioTools Charter Amendment Proposal. To approve an amendment to the Standard BioTools Eighth Amended and Restated Certificate of Incorporation, as amended (the "Standard BioTools Charter"), to increase the total number of shares of Standard BioTools Common Stock authorized for issuance thereunder from 400,000,000 shares to 600,000,000 shares (the "Standard BioTools Charter Amendment Proposal");
STANDARD BIOTOOLS INC.’s own tally for this item (“2. To approve the Charter Amendment (the "Standard BioTools Charter Amendment Proposal")”): 125,698,245 for, 5,230,711 against, per its Form 8-K filed January 5, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 19 asset managers below reported 11,930,519 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,068,266 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 2,195,369 | 0 | 0 | 0 | For |
| Neuberger Berman | 1,468,160 | 0 | 0 | 0 | For |
| Morgan Stanley | 1,295,362 | 0 | 0 | 0 | For |
| NEEDHAM FUNDS INC | 1,190,000 | 0 | 0 | 0 | For |
| Equitable | 597,551 | 0 | 0 | 0 | For |
| Fidelity | 538,365 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 212,000 | 0 | 0 | 0 | For |
| NEXPOINT FUNDS I | 154,262 | 0 | 0 | 0 | For |
| BlackRock | 76,562 | 0 | 0 | 0 | For |
| BNY Mellon | 52,908 | 0 | 0 | 0 | For |
| Charles Schwab | 31,192 | 0 | 0 | 0 | For |
| Dimensional | 20,355 | 0 | 0 | 0 | For |
| Northern Trust | 16,964 | 0 | 0 | 0 | For |
| Victory Capital | 8,484 | 0 | 0 | 0 | For |
| Nationwide | 2,446 | 0 | 0 | 0 | For |
| John Hancock | 1,624 | 0 | 0 | 0 | For |
| Guggenheim | 454 | 0 | 0 | 0 | For |
| Series Portfolios Trust | 195 | 0 | 0 | 0 | For |
Meeting held January 4, 2024.
Combines 2 wordings of this item as funds reported it.
94% of fund votes cast · no official result
Description as filed by funds: Standard BioTools Adjournment Proposal. To approve adjournments of the Standard BioTools Special Meeting from time to time, if necessary or appropriate, to solicit additional proxies in favor of the Standard BioTools Share Issuance Proposal and the Standard BioTools Charter Amendment Proposal if there are insufficient votes at the time of such adjournment to approve such proposals or to ensure that any supplement or amendment to the accompanying joint proxy statement/prospectus is timely provided to Standard BioTools stockholders (the "Standard BioTools Adjournment Proposal" and, together with the Standard BioTools Share Issuance Proposal, the Standard BioTools Charter Amendment Proposal, the Standard BioTools Advisory Compensation Proposal and the Standard BioTools Equity Incentive Plan Amendment Proposal, the "Standard BioTools Proposals").
The 15 asset managers below reported 7,850,899 for, 538,365 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,068,266 | 0 | 0 | 0 | For |
| Neuberger Berman | 1,468,160 | 0 | 0 | 0 | For |
| Morgan Stanley | 1,295,362 | 0 | 0 | 0 | For |
| Equitable | 597,551 | 0 | 0 | 0 | For |
| Fidelity | 0 | 538,365 | 0 | 0 | Against |
| BRIDGEWAY FUNDS INC | 212,000 | 0 | 0 | 0 | For |
| BlackRock | 76,562 | 0 | 0 | 0 | For |
| BNY Mellon | 52,908 | 0 | 0 | 0 | For |
| Charles Schwab | 31,192 | 0 | 0 | 0 | For |
| Dimensional | 20,355 | 0 | 0 | 0 | For |
| Northern Trust | 16,964 | 0 | 0 | 0 | For |
| Victory Capital | 8,484 | 0 | 0 | 0 | For |
| Nationwide | 2,446 | 0 | 0 | 0 | For |
| Guggenheim | 454 | 0 | 0 | 0 | For |
| Series Portfolios Trust | 195 | 0 | 0 | 0 | For |
Meeting held June 27, 2024.
96% Approved · of votes cast
Description as filed by funds: To approve an amendment to our Amended and Restated 2011 Equity Incentive Plan, as amended, to increase the number of shares of common stock available for issuance thereunder by 19,125,000 shares.
STANDARD BIOTOOLS INC.’s own tally for this item (“4. Approval of the Amendment to the Amended and Restated 2011 Equity Incentive Plan”): 219,832,074 for, 10,192,031 against — passed, per its Form 8-K filed July 1, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The proposal to approve the amendment to the Plan to increase the shares of common stock reserved thereunder by 19,125,000 shares was approved by the following votes:”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 23 asset managers below reported 38,282,814 for, 156,591 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| ARK ETF Trust | 13,046,212 | 0 | 0 | 0 | For |
| Vanguard | 12,987,923 | 0 | 0 | 0 | For |
| Morgan Stanley | 3,735,804 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 2,153,269 | 0 | 0 | 0 | For |
| Equitable | 1,786,199 | 0 | 0 | 0 | For |
| Fidelity | 1,280,779 | 0 | 0 | 0 | For |
| Neuberger Berman | 1,176,340 | 0 | 0 | 0 | For |
| BlackRock | 866,875 | 0 | 0 | 0 | For |
| NORTHERN LIGHTS FUND TRUST II | 541,597 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 260,783 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 177,000 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 119,504 | 0 | 0 | Against |
| Charles Schwab | 111,584 | 0 | 0 | 0 | For |
| Dimensional | 72,060 | 0 | 0 | 0 | For |
| Victory Capital | 36,686 | 0 | 0 | 0 | For |
| American Century | 0 | 26,410 | 0 | 0 | Against |
| BNY Mellon | 23,182 | 0 | 0 | 0 | For |
| Invesco | 18,127 | 0 | 0 | 0 | For |
| State Street | 0 | 10,677 | 0 | 0 | Against |
| John Hancock | 6,488 | 0 | 0 | 0 | For |
| Nationwide | 1,451 | 0 | 0 | 0 | For |
| Guggenheim | 454 | 0 | 0 | 0 | For |
| New York Life | 1 | 0 | 0 | 0 | For |
Meeting held January 4, 2024.
Combines 4 wordings of this item as funds reported it.
91% Majority: yes · of votes cast
Description as filed by funds: Standard BioTools 2011 Equity Incentive Plan Amendment Proposal. To approve an amendment to the Standard BioTools Amended and Restated 2011 Equity Incentive Plan, as amended (the "A&R 2011 Plan"), to increase the aggregate number of shares of Standard BioTools Common Stock that are available for issuance thereunder by 15,000,000 shares (the "Standard BioTools Equity Incentive Plan Amendment Proposal"); and
STANDARD BIOTOOLS INC.’s own tally for this item (“4. To approve the A&R 2011 Plan Amendment”): 119,362,194 for, 11,536,749 against, per its Form 8-K filed January 5, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 20 asset managers below reported 9,779,746 for, 2,212,333 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,068,266 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 0 | 2,195,369 | 0 | 0 | Against |
| Neuberger Berman | 1,468,160 | 0 | 0 | 0 | For |
| Morgan Stanley | 1,295,362 | 0 | 0 | 0 | For |
| NEEDHAM FUNDS INC | 1,190,000 | 0 | 0 | 0 | For |
| Equitable | 597,551 | 0 | 0 | 0 | For |
| Fidelity | 538,365 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 212,000 | 0 | 0 | 0 | For |
| NEXPOINT FUNDS I | 154,262 | 0 | 0 | 0 | For |
| BlackRock | 76,562 | 0 | 0 | 0 | For |
| ALGERT GLOBAL LLC | 61,560 | 0 | 0 | 0 | For |
| BNY Mellon | 52,908 | 0 | 0 | 0 | For |
| Charles Schwab | 31,192 | 0 | 0 | 0 | For |
| Dimensional | 20,355 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 16,964 | 0 | 0 | Against |
| Victory Capital | 8,484 | 0 | 0 | 0 | For |
| Nationwide | 2,446 | 0 | 0 | 0 | For |
| John Hancock | 1,624 | 0 | 0 | 0 | For |
| Guggenheim | 454 | 0 | 0 | 0 | For |
| Series Portfolios Trust | 195 | 0 | 0 | 0 | For |
Meeting held June 27, 2024.
Combines 8 wordings of this item as funds reported it.
87% Approved · of votes cast
Description as filed by funds: To approve, on an advisory basis, the compensation of our named executive officers as disclosed in this proxy statement.
STANDARD BIOTOOLS INC.’s own tally for this item (“2. Advisory Vote on Approval of Executive Compensation”): 200,835,452 for, 28,960,018 against — passed, per its Form 8-K filed July 1, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The proposal to approve, on an advisory basis, the compensation of the Company's named executive officers for the year ended December 31, 2023 was approved by the following votes:”
Support: 87% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| ARK ETF Trust | 13,046,212 | 0 | 0 | 0 | For |
| Vanguard | 12,987,923 | 0 | 0 | 0 | For |
| Morgan Stanley | 3,735,804 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 2,153,269 | 0 | 0 | 0 | For |
| Equitable | 1,739,957 | 46,242 | 0 | 0 | For |
| Fidelity | 1,176,402 | 104,377 | 0 | 0 | Mixed |
| Neuberger Berman | 1,176,340 | 0 | 0 | 0 | For |
| NEEDHAM FUNDS INC | 950,000 | 0 | 0 | 0 | For |
| BlackRock | 0 | 866,875 | 0 | 0 | Against |
| NORTHERN LIGHTS FUND TRUST II | 541,597 | 0 | 0 | 0 | For |
| PARADIGM FUNDS | 0 | 301,600 | 0 | 0 | Against |
| TRUST FOR PROFESSIONAL MANAGERS | 260,783 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 177,000 | 0 | 0 | Against |
| Northern Trust | 119,504 | 0 | 0 | 0 | For |
| Charles Schwab | 111,584 | 0 | 0 | 0 | For |
| Dimensional | 0 | 72,060 | 0 | 0 | Against |
| Victory Capital | 0 | 36,686 | 0 | 0 | Against |
| American Century | 0 | 26,410 | 0 | 0 | Against |
| BNY Mellon | 0 | 23,182 | 0 | 0 | Against |
| Invesco | 0 | 18,127 | 0 | 0 | Against |
| State Street | 10,677 | 0 | 0 | 0 | For |
| John Hancock | 0 | 6,488 | 0 | 0 | Against |
| Nationwide | 0 | 1,451 | 0 | 0 | Against |
| Guggenheim | 0 | 454 | 0 | 0 | Against |
| New York Life | 0 | 1 | 0 | 0 | Against |
Fund voting reports, all 25 managers: 38,010,052 for, 1,680,953 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Morgan Stanley | 11,078,216 | 0 | 0 | 0 | For |
| Nikko Asset Management Americas, Inc. | 0 | 9,349,418 | 0 | 0 | Against |
| BlackRock | 14,370 | 4,286,180 | 0 | 0 | Against |
| Neuberger Berman | 3,761,522 | 0 | 0 | 0 | For |
| PRIMECAP MANAGEMENT CO/CA/ | 3,008,643 | 0 | 0 | 0 | For |
| Indaba Capital Management, L.P. | 0 | 2,879,857 | 0 | 0 | Against |
| BALYASNY ASSET MANAGEMENT L.P. | 2,032,290 | 0 | 0 | 0 | For |
| Nikko Asset Management Co., Ltd. | 0 | 1,677,117 | 0 | 0 | Against |
| Slate Path Capital LP | 1,563,477 | 0 | 0 | 0 | For |
| Tikvah Management LLC | 1,461,947 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,439,488 | 0 | 0 | 0 | For |
| State Street | 1,087,961 | 82,899 | 0 | 0 | Mixed |
| Invenomic Capital Management LP | 985,564 | 0 | 0 | 0 | For |
| Northern Trust | 687,341 | 8,331 | 0 | 0 | For |
| STRS OHIO | 0 | 454,169 | 0 | 0 | Against |
| Redmile Group, LLC | 411,631 | 0 | 0 | 0 | For |
| Renaissance | 0 | 400,421 | 0 | 0 | Against |
| Magnetar Financial LLC | 0 | 334,480 | 0 | 0 | Against |
| Laurion Capital Management LP | 0 | 300,010 | 0 | 0 | Against |
| Vanguard | 253,953 | 0 | 0 | 0 | For |
| Pacific Capital Partners Ltd | 0 | 250,000 | 0 | 0 | Against |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 0 | 236,479 | 0 | 0 | Against |
| HighTower Advisors, LLC | 0 | 231,010 | 0 | 0 | Against |
| Two Sigma | 0 | 230,694 | 0 | 0 | Against |
| Citadel | 228,021 | 0 | 0 | 0 | For |
Institutional-manager reports, all 110 managers: 28,958,205 for, 21,645,089 against, 67 withheld. Showing the 25 largest; see all in the interactive database.
Meeting held January 4, 2024.
Combines 8 wordings of this item as funds reported it.
91% Majority: yes · of votes cast
Description as filed by funds: Standard BioTools Advisory Compensation Proposal. To approve, on a non-binding, advisory basis, the compensation that may become payable to Standard BioTools' named executive officers and to SomaLogic's Chief Executive Officer that is based on or otherwise relates to the Merger, as disclosed in "The Merger - Interests of Standard BioTools Directors and Executive Officers in the Merger - Quantification of Potential Payments to Standard BioTools Named Executive Officers and SomaLogic's Chief Executive Officer in Connection with the Merger" beginning on page 127 of the accompanying joint proxy statement/prospectus (the "Standard BioTools Advisory Compensation Proposal");
STANDARD BIOTOOLS INC.’s own tally for this item (“3. To approve, on a non-binding, advisory basis, the compensation that may become payable to Standard BioTools' named executive officers and to SomaLogic's Chief Executive Officer that is based on or otherwise relates to”): 119,441,699 for, 11,267,991 against, per its Form 8-K filed January 5, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,068,266 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 0 | 2,195,369 | 0 | 0 | Against |
| Neuberger Berman | 1,468,160 | 0 | 0 | 0 | For |
| Morgan Stanley | 1,295,362 | 0 | 0 | 0 | For |
| NEEDHAM FUNDS INC | 1,190,000 | 0 | 0 | 0 | For |
| Equitable | 597,551 | 0 | 0 | 0 | For |
| Fidelity | 538,365 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 212,000 | 0 | 0 | 0 | For |
| NEXPOINT FUNDS I | 154,262 | 0 | 0 | 0 | For |
| BlackRock | 76,562 | 0 | 0 | 0 | For |
| BNY Mellon | 52,908 | 0 | 0 | 0 | For |
| Charles Schwab | 31,192 | 0 | 0 | 0 | For |
| Dimensional | 20,355 | 0 | 0 | 0 | For |
| Northern Trust | 16,964 | 0 | 0 | 0 | For |
| Victory Capital | 8,484 | 0 | 0 | 0 | For |
| Nationwide | 2,446 | 0 | 0 | 0 | For |
| John Hancock | 1,624 | 0 | 0 | 0 | For |
| Guggenheim | 454 | 0 | 0 | 0 | For |
| Series Portfolios Trust | 195 | 0 | 0 | 0 | For |
Fund voting reports, all 19 managers: 9,735,150 for, 2,195,369 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Indaba Capital Management, L.P. | 7,446,229 | 0 | 0 | 0 | For |
| Morgan Stanley | 3,797,372 | 0 | 0 | 0 | For |
| Neuberger Berman | 3,389,941 | 0 | 0 | 0 | For |
| PRIMECAP MANAGEMENT CO/CA/ | 0 | 3,059,943 | 0 | 0 | Against |
| BlackRock | 1,169,292 | 0 | 0 | 0 | For |
| BOOTHBAY FUND MANAGEMENT, LLC | 774,014 | 0 | 0 | 0 | For |
| BALYASNY ASSET MANAGEMENT L.P. | 731,756 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 609,345 | 0 | 0 | 0 | For |
| STRS OHIO | 483,940 | 0 | 0 | 0 | For |
| State Street | 279,537 | 0 | 0 | 0 | For |
| Renaissance | 272,060 | 0 | 0 | 0 | For |
| DIKER MANAGEMENT LLC | 224,824 | 0 | 0 | 0 | For |
| HighTower Advisors, LLC | 188,700 | 0 | 0 | 0 | For |
| ROCKEFELLER FINANCIAL LLC | 152,208 | 0 | 0 | 0 | For |
| SILVERBACK ASSET MANAGEMENT LLC | 0 | 125,000 | 0 | 0 | Against |
| BNY Mellon | 105,816 | 0 | 0 | 0 | For |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 92,493 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 86,105 | 0 | 0 | 0 | For |
| Polar Capital Holdings Plc | 56,585 | 0 | 0 | 0 | For |
| RBC Dominion Securities Inc. | 50,235 | 0 | 0 | 0 | For |
| SEI | 49,616 | 0 | 0 | 0 | For |
| T. Rowe Price | 38,400 | 0 | 0 | 0 | For |
| Citadel | 36,894 | 0 | 0 | 0 | For |
| NEEDHAM INVESTMENT MANAGEMENT LLC | 34,435 | 0 | 0 | 0 | For |
| Charles Schwab | 31,192 | 0 | 0 | 0 | For |
Institutional-manager reports, all 68 managers: 20,291,904 for, 3,185,213 against, 264 withheld. Showing the 25 largest; see all in the interactive database.
Meeting held June 5, 2024; no official results are on file for this meeting.
Combines 2 wordings of this item as funds reported it.
99.9% Fund and manager reports combined; may count the same shares twice · no official result
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| NEEDHAM FUNDS INC | 950,000 | 0 | 0 | 0 | For |
Fund voting reports, all 1 managers: 950,000 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| NEEDHAM INVESTMENT MANAGEMENT LLC | 34,435 | 0 | 0 | 0 | For |
| BBR PARTNERS, LLC | 7,886 | 0 | 0 | 0 | For |
| BlackRock | 3,568 | 0 | 0 | 0 | For |
| Bleakley Financial Group, LLC | 438 | 0 | 0 | 0 | For |
| BCS Wealth Management | 200 | 0 | 0 | 0 | For |
| PINNACLE ASSOCIATES LTD | 200 | 0 | 0 | 0 | For |
| Mirador Capital Partners LP | 0 | 0 | 0 | 67 | Withhold |
| Capital Group | 40 | 0 | 0 | 0 | For |
Institutional-manager reports, all 8 managers: 46,767 for, 67 withheld.
Meeting held June 27, 2024.
99.8% Approved · of votes cast
Description as filed by funds: To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2024.
STANDARD BIOTOOLS INC.’s own tally for this item (“3. Ratification of Appointment of Independent Registered Public Accounting Firm”): 291,606,384 for, 383,526 against — passed, per its Form 8-K filed July 1, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024 was approved by the following vote:”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 23 asset managers below reported 38,439,405 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| ARK ETF Trust | 13,046,212 | 0 | 0 | 0 | For |
| Vanguard | 12,987,923 | 0 | 0 | 0 | For |
| Morgan Stanley | 3,735,804 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 2,153,269 | 0 | 0 | 0 | For |
| Equitable | 1,786,199 | 0 | 0 | 0 | For |
| Fidelity | 1,280,779 | 0 | 0 | 0 | For |
| Neuberger Berman | 1,176,340 | 0 | 0 | 0 | For |
| BlackRock | 866,875 | 0 | 0 | 0 | For |
| NORTHERN LIGHTS FUND TRUST II | 541,597 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 260,783 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 177,000 | 0 | 0 | 0 | For |
| Northern Trust | 119,504 | 0 | 0 | 0 | For |
| Charles Schwab | 111,584 | 0 | 0 | 0 | For |
| Dimensional | 72,060 | 0 | 0 | 0 | For |
| Victory Capital | 36,686 | 0 | 0 | 0 | For |
| American Century | 26,410 | 0 | 0 | 0 | For |
| BNY Mellon | 23,182 | 0 | 0 | 0 | For |
| Invesco | 18,127 | 0 | 0 | 0 | For |
| State Street | 10,677 | 0 | 0 | 0 | For |
| John Hancock | 6,488 | 0 | 0 | 0 | For |
| Nationwide | 1,451 | 0 | 0 | 0 | For |
| Guggenheim | 454 | 0 | 0 | 0 | For |
| New York Life | 1 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 79,395,035 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | ARK ETF Trust | 16.43% |
| 2 | Vanguard | 16.36% |
| 3 | Morgan Stanley | 4.71% |
| 4 | PRIMECAP Odyssey Funds | 2.71% |
| 5 | Equitable | 2.25% |
| 6 | Fidelity | 1.61% |
| 7 | Neuberger Berman | 1.48% |
| 8 | NEEDHAM FUNDS INC | 1.20% |
| 9 | BlackRock | 1.09% |
| 10 | NORTHERN LIGHTS FUND TRUST II | 0.68% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Morgan Stanley | 13.95% |
| 2 | Nikko Asset Management Americas, Inc. | 11.78% |
| 3 | BlackRock | 5.42% |
| 4 | Neuberger Berman | 4.74% |
| 5 | PRIMECAP MANAGEMENT CO/CA/ | 3.79% |
| 6 | Indaba Capital Management, L.P. | 3.63% |
| 7 | BALYASNY ASSET MANAGEMENT L.P. | 2.56% |
| 8 | Nikko Asset Management Co., Ltd. | 2.11% |
| 9 | Slate Path Capital LP | 1.97% |
| 10 | Tikvah Management LLC | 1.84% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| S | 86.91% | 13D |
| BlackRock | 31.39% | 13F |
| Vanguard Group | 21.72% | 13F |
| Millennium Management | 18.10% | 13F |
| Morgan Stanley | 8.00% | 13F |
| Geode Capital | 3.41% | 13F |
| State Street | 1.69% | 13F |
| Goldman Sachs | 1.63% | 13F |
| Dimensional Fund Advisors | 1.60% | 13F |
| Renaissance Technologies | 1.58% | 13F |
Percentages above are of 79,395,035 shares outstanding, as reported by STANDARD BIOTOOLS INC. on its Form 10-Q dated November 3, 2023 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from STANDARD BIOTOOLS INC.’s 10-Q dated November 3, 2023. This page is a static snapshot rebuilt weekly on October 14, 2026; a live search always shows the current data.
At STANDARD BIOTOOLS INC.'s 3 shareholder meetings in the 2023-2024 proxy season (held January 4, 2024, June 5, 2024 and June 27, 2024), 141 asset managers reported how they voted in their SEC Form N-PX filings, covering 632 separate fund positions. Their filings are grouped here into 11 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item of the season, voted at the meeting held June 27, 2024 — To approve, on an advisory basis, the compensation of our named executive officers as disclosed… — STANDARD BIOTOOLS INC.'s filing reports the proposal as approved, with 87% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: STANDARD BIOTOOLS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on July 1, 2024.
STANDARD BIOTOOLS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.
Download data (CSV): ballot items · votes by manager · column guide.